{"DataElement":{"publicId":"3228237","version":"1","preferredName":"Breast Tumor Post Neoadjuvant Therapy Axillary Lymph Node Response Status","preferredDefinition":"the response of lymph nodes found in the armpit that drain the lymph channels from the breast following treatment designed to be used as a first step toward shrinking a breast tumor and in evaluating response to drugs and other agents.","longName":"3228236v1.0:3228226v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3228236","version":"1","preferredName":"Breast Tumor Post Neoadjuvant Therapy Axillary Lymph Node Response","preferredDefinition":"information related to the response of lymph nodes found in the armpit that drain the lymph channels from the breast following treatment designed to be used as a first step toward shrinking a breast tumor and in evaluating response to drugs and other agents.","longName":"2206465v1.0:3228234v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206465","version":"1","preferredName":"Breast Neoplasm","preferredDefinition":"One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.:(NEE-o-PLAY-zha) Abnormal and uncontrolled cell growth.","longName":"C12971:C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast","conceptCode":"C12971","definition":"One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0428-F64A-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3228234","version":"1","preferredName":"Post Neoadjuvant Therapy Axillary Lymph Node Response","preferredDefinition":"Post; occuring after.:Treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents. Induction therapy is followed by additional therapy to eliminate whatever cancer remains.:Lymph nodes found in the armpit that drain the lymph channels from the breast.:In medicine, an improvement related to treatment.","longName":"C38008:C15665:C12904:C50995","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Neoadjuvant Therapy","conceptCode":"C15665","definition":"Therapy administered prior to the primary treatment for the purpose of making the primary treatment more effective.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Axillary Lymph Node","conceptCode":"C12904","definition":"One of approximately 20-30 lymph nodes in chain formation that traverse the concavity of the underarm to the clavicle.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A147E53C-EC6B-A077-E040-BB89AD437677","latestVersionIndicator":"Yes","beginDate":"2011-04-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-19","modifiedBy":"ONEDATA","dateModified":"2011-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A147E53C-EC7C-A077-E040-BB89AD437677","latestVersionIndicator":"Yes","beginDate":"2011-04-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-19","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3228226","version":"1","preferredName":"Neoplasm Neoadjuvant Therapy Response Status","preferredDefinition":"A condition or state of neoplasm following neoadjuvant therapy at a particular time.","longName":"3228226v1.0","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"65","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Progression [e.g., sum diameters >= 20% increase]","valueDescription":"Progression","ValueMeaning":{"publicId":"3228227","version":"1","preferredName":"Progression","longName":"3228227","preferredDefinition":"Sum of tumor diameters >=20% increase","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A147C0E5-77C2-4A7D-E040-BB89AD432370","latestVersionIndicator":"Yes","beginDate":"2011-04-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A147C0E5-77DB-4A7D-E040-BB89AD432370","beginDate":"2011-04-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-19","modifiedBy":"ONEDATA","dateModified":"2011-04-19","deletedIndicator":"No"},{"value":"Partial response [e.g., sum of diameters >=30% reduction]","valueDescription":"Partial response","ValueMeaning":{"publicId":"3228228","version":"1","preferredName":"Partial response","longName":"3228228","preferredDefinition":"Sum of tumor diameters >=30% reduction","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A147C0E5-77E5-4A7D-E040-BB89AD432370","latestVersionIndicator":"Yes","beginDate":"2011-04-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A147C0E5-77FD-4A7D-E040-BB89AD432370","beginDate":"2011-04-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-19","modifiedBy":"ONEDATA","dateModified":"2011-04-19","deletedIndicator":"No"},{"value":"Clinically complete response but no pathological information","valueDescription":"Clinically complete response but no pathological information","ValueMeaning":{"publicId":"3228229","version":"1","preferredName":"Clinically complete response but no pathological information","longName":"3228229","preferredDefinition":"Clinically complete response but no pathological information","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A147C0E5-7808-4A7D-E040-BB89AD432370","latestVersionIndicator":"Yes","beginDate":"2011-04-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A147C0E5-7821-4A7D-E040-BB89AD432370","beginDate":"2011-04-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-19","modifiedBy":"ONEDATA","dateModified":"2011-04-19","deletedIndicator":"No"},{"value":"Clinically complete response with tumour cells remaining","valueDescription":"Clinically complete response with tumour cells remaining","ValueMeaning":{"publicId":"3228230","version":"1","preferredName":"Clinically complete response with tumour cells remaining","longName":"3228230","preferredDefinition":"Clinically complete response with tumour cells remaining","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A147C0E5-782B-4A7D-E040-BB89AD432370","latestVersionIndicator":"Yes","beginDate":"2011-04-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A147C0E5-7844-4A7D-E040-BB89AD432370","beginDate":"2011-04-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-19","modifiedBy":"ONEDATA","dateModified":"2011-04-19","deletedIndicator":"No"},{"value":"Clinically complete response (cCR) with negative pathology","valueDescription":"Clinically complete response (cCR) with negative pathology","ValueMeaning":{"publicId":"3228231","version":"1","preferredName":"Clinically complete response (cCR) with negative pathology","longName":"3228231","preferredDefinition":"Clinically complete response (cCR) with negative pathology","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A147C0E5-784E-4A7D-E040-BB89AD432370","latestVersionIndicator":"Yes","beginDate":"2011-04-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A147C0E5-7867-4A7D-E040-BB89AD432370","beginDate":"2011-04-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-19","modifiedBy":"ONEDATA","dateModified":"2011-04-19","deletedIndicator":"No"},{"value":"Neoadjuvant not given","valueDescription":"No Administration Neoadjuvant Therapy","ValueMeaning":{"publicId":"3228232","version":"1","preferredName":"No Administration Neoadjuvant Therapy","longName":"3228232","preferredDefinition":"The non-affirmative response to a question.: Performing or possessing executive duties; acting as a supervisor or manager.: Treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents. Induction therapy is followed by additional therapy to eliminate whatever cancer remains.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Administration, Management","conceptCode":"C48905","definition":"Performing or possessing executive duties; acting as a supervisor or manager.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoadjuvant Therapy","conceptCode":"C15665","definition":"Therapy administered prior to the primary treatment for the purpose of making the primary treatment more effective.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A147C0E5-7875-4A7D-E040-BB89AD432370","latestVersionIndicator":"Yes","beginDate":"2011-04-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A147C0E5-788E-4A7D-E040-BB89AD432370","beginDate":"2011-04-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-19","modifiedBy":"ONEDATA","dateModified":"2011-04-19","deletedIndicator":"No"},{"value":"Stable","valueDescription":"Stable","ValueMeaning":{"publicId":"2570725","version":"1","preferredName":"Stable","longName":"2570725","preferredDefinition":"Stable; subject to little fluctuation; showing little if any change.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable","conceptCode":"C30103","definition":"Subject to little fluctuation; showing little if any change.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E152-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"REEVESD","dateModified":"2011-12-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A147C0E5-7898-4A7D-E040-BB89AD432370","beginDate":"2011-04-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-19","modifiedBy":"ONEDATA","dateModified":"2011-04-19","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"3089560","version":"1","preferredName":"Other","longName":"3089560","preferredDefinition":"Other treatment cannot be appropriately assigned to specific data item (i.e. phlebotomy, transfusion, and aspirin or other disease modifying agent). Use for hematopoietic diseases.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87063ADB-2EE9-3A83-E040-BB89AD430877","latestVersionIndicator":"Yes","beginDate":"2010-05-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2010-05-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A147C0E5-78A3-4A7D-E040-BB89AD432370","beginDate":"2011-04-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-19","modifiedBy":"ONEDATA","dateModified":"2011-04-19","deletedIndicator":"No"},{"value":"No evidence of pathological response","valueDescription":"No Evidence of Disease Pathologic Disease Response","ValueMeaning":{"publicId":"6004482","version":"1","preferredName":"No Evidence of Disease Pathologic Disease Response","longName":"6004482","preferredDefinition":"Diagnostic tests fail to detect presence of disease.: Caused by or altered by or manifesting disease or pathology.: The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No Evidence of Disease","conceptCode":"C40413","definition":"Diagnostic tests fail to detect presence of disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Pathologic","conceptCode":"C25610","definition":"Caused by or altered by or manifesting disease or pathology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BAFCE2D-24EF-69AA-E053-F662850A9D40","latestVersionIndicator":"Yes","beginDate":"2017-10-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-10-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BAFCE2D-2508-69AA-E053-F662850A9D40","beginDate":"2017-10-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-10-16","modifiedBy":"ONEDATA","dateModified":"2017-10-16","deletedIndicator":"No"},{"value":"Complete response nodes","valueDescription":"Clinical Complete Response Lymph Node","ValueMeaning":{"publicId":"6004483","version":"1","preferredName":"Clinical Complete Response Lymph Node","longName":"6004483","preferredDefinition":"The disappearance of all signs of cancer based on physical exam, such as palpation.: A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Complete Response","conceptCode":"C123574","definition":"The disappearance of all signs of cancer based on physical exam, such as palpation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lymph Node","conceptCode":"C12745","definition":"A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BAFCE2D-2515-69AA-E053-F662850A9D40","latestVersionIndicator":"Yes","beginDate":"2017-10-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-10-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BAFCE2D-252E-69AA-E053-F662850A9D40","beginDate":"2017-10-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-10-16","modifiedBy":"ONEDATA","dateModified":"2017-10-16","deletedIndicator":"No"},{"value":"Complete response breast","valueDescription":"Clinical Complete Response Breast","ValueMeaning":{"publicId":"6004484","version":"1","preferredName":"Clinical Complete Response Breast","longName":"6004484","preferredDefinition":"The disappearance of all signs of cancer based on physical exam, such as palpation.: One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Complete Response","conceptCode":"C123574","definition":"The disappearance of all signs of cancer based on physical exam, such as palpation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Breast","conceptCode":"C12971","definition":"One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BAFCE2D-253B-69AA-E053-F662850A9D40","latestVersionIndicator":"Yes","beginDate":"2017-10-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-10-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BAFCE2D-2554-69AA-E053-F662850A9D40","beginDate":"2017-10-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-10-16","modifiedBy":"ONEDATA","dateModified":"2017-10-16","deletedIndicator":"No"},{"value":"Complete response both breast and nodes","valueDescription":"Clinical Complete Response","ValueMeaning":{"publicId":"5838504","version":"1","preferredName":"Clinical Complete Response","longName":"5838504","preferredDefinition":"The disappearance of all signs of cancer based on physical exam, such as palpation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Complete Response","conceptCode":"C123574","definition":"The disappearance of all signs of cancer based on physical exam, such as palpation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"506DC049-356A-7059-E053-F662850A6D2C","latestVersionIndicator":"Yes","beginDate":"2017-05-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-05-26","modifiedBy":"CLOHNES","dateModified":"2023-11-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BAFCE2D-2568-69AA-E053-F662850A9D40","beginDate":"2017-10-16","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-10-16","modifiedBy":"ONEDATA","dateModified":"2017-10-16","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2404650","version":"1","preferredName":"Status","preferredDefinition":"A condition or state at a particular time.","longName":"C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"005AD6E5-057F-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A147C0E5-77AD-4A7D-E040-BB89AD432370","latestVersionIndicator":"Yes","beginDate":"2011-04-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-19","modifiedBy":"MORENOC","dateModified":"2017-10-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Axilla response after neoadju","type":"Preferred Question Text","description":"Axilla response after neoadjuvant therapy","url":null,"context":"CTEP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A147E53C-ED09-A077-E040-BB89AD437677","latestVersionIndicator":"Yes","beginDate":"2011-04-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-04-19","modifiedBy":"CAMPBELB","dateModified":"2011-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}